Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Academics and course directors offer an insight into Oxford Medical Sciences undergraduate courses

Image courtesy of Shutterstock

Attracting the very best applicants from all parts of the UK remains a high priority for our undergraduate courses. With this in mind, Deputy Director of Pre-clinical Studies Prof. Chris Norbury explained the six-year Medicine and three-year Biomedical Sciences courses to a total of around 1,750 potential applicants at the Oxford-Cambridge Student Conferences, held across the country over two weeks in March. The four-year Biochemistry course was similarly covered by Kathryn Scott and Mark Wormald.

Each conference was a day-long event, with venues ranging from football stadia (St James' Park, Newcastle and the Liberty Stadium, Swansea) to race courses (Epsom and Aintree), and included sessions on student finance and how to make a competitive application, as well as subject-specific presentations and Q&A. Current undergraduates local to each area played key roles as 'student ambassadors', helping the school students attending the Conferences to appreciate that Oxbridge entry is an achievable goal.

Prof. Norbury commented: "The Conferences provide an efficient way of making direct contact with a substantial proportion of those year 12 students who are seriously thinking about applying for our courses. We were able to answer a wide range of questions from students and their teachers, and to offer encouragement to all those with a genuine interest in the science that makes medicine work. These events are organised jointly with Cambridge in a collaborative spirit, but informal feedback from participants suggests the Oxford courses were viewed very positively by comparison with their Cambridge counterparts!".

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.